(PharmaNewsWire.Com, October 02, 2020 ) The growth of the organ preservation market is mainly driven by the increasing incidence of multi-organ failure, the growing geriatric population, the rising number of organ transplants and organ donors, and increasing initiatives to encourage organ donations.
“By Solution, University of Wisconsin (UW) holds the largest market share.”
Based on the Solution, the segment is divided into UW, Custodial HTK, Perfadex and Other solutions (EuroCollins and Celsior). In 2019, the UW solution accounted for the highest share in 2019. The UW solution is used for the flushing and storage of kidneys, liver, and pancreas. It was the first intracellular preservation medium, considered the gold standard for organ preservation.
“By Organ type, Kidney holds the largest market share and lungs is expected to grow at the highest CAGR in the forecast period.”
Kidneys account for the largest market share in the organ segment. Renal transplantation is considered the treatment of choice for patients with end-stage renal disease (ESRD) or kidney failure, diabetes etc. are all cause for the growth of this segment. Lungs market is expected to grow at a faster rate in the period of 2019 to 2024. This is mainly due to the rising prevalence of COPD and other target diseases & disorders necessitating lung transplantation.
“The Asia Pacific to witness the highest growth during the forecast period.”
Asia Pacific is expected to grow at the highest CAGR during the forecast period of 2019–2024. The major factors driving the growth of the Asia Pacific market include favorable government initiatives, increased awareness in people and increased organ donations.
XVIVO Perfusion AB (Sweden), Paragonix Technologies (US), Dr. Franz Kohler Chemie GMBH (Germany) are the leading players in the organ preservation market.
The growth of these players can be attributed to various product launches & approvals, acquisitions, agreements, partnerships, and collaborations to increase their shares in the organ preservation market.
MarketsandMarkets™ provides quantified B2B research on 30,000 high growth niche opportunities/threats which will impact 70% to 80% of worldwide companies’ revenues. Currently servicing 7500 customers worldwide including 80% of global Fortune 1000 companies as clients. Almost 75,000 top officers across eight industries worldwide approach MarketsandMarkets™ for their painpoints around revenues decisions.
Our 850 fulltime analyst and SMEs at MarketsandMarkets™ are tracking global high growth markets following the "Growth Engagement Model – GEM". The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write "Attack, avoid and defend" strategies, identify sources of incremental revenues for both the company and its competitors. MarketsandMarkets™ now coming up with 1,500 MicroQuadrants (Positioning top players across leaders, emerging companies, innovators, strategic players) annually in high growth emerging segments. MarketsandMarkets™ is determined to benefit more than 10,000 companies this year for their revenue planning and help them take their innovations/disruptions early to the market by providing them research ahead of the curve.
MarketsandMarkets’s flagship competitive intelligence and market research platform, "Knowledgestore" connects over 200,000 markets and entire value chains for deeper understanding of the unmet insights along with market sizing and forecasts of niche markets.
We are pleased to offer you this exciting, new, and entirely free professional resource. Visit our Free Biotechnology & Pharmaceuticals resource center today to browse our selection of 600+ complimentary Biotechnology & Pharmaceuticals magazines, white papers, webinars, podcasts, and more. Get popular titles including:
